CD3 Antibody (G4.18) - BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-43458
Key Product Details
Species Reactivity
Validated:
Rat
Cited:
Rat
Applications
Validated:
Flow Cytometry, Immunohistochemistry, Immunohistochemistry-Paraffin, Immunoprecipitation, Western Blot
Cited:
Immunohistochemistry-Paraffin
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG3 Kappa Clone # G4.18
Format
BSA Free
Concentration
0.5 mg/ml
Product Specifications
Immunogen
This CD3 antibody was developed against CD3.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG3 Kappa
Theoretical MW
21.3 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Scientific Data Images for CD3 Antibody (G4.18) - BSA Free
Flow Cytometry: CD3 Antibody (G4.18) - BSA Free [NBP1-43458]
Flow Cytometry: CD3 Antibody (G4.18) [NBP1-43458] - Analysis using the Biotin conjugate of NBP1-43458. Staining of rat splenocytes with anti-Rat CD45R (B220) FITC and staining buffer (autofluorescence) (left) or 0.125 ug of anti-Rat CD3 Biotin (right) followed by Streptavidin PE.Flow Cytometry: CD3 Antibody (G4.18) - BSA Free [NBP1-43458]
Flow Cytometry: CD3 Antibody (G4.18) [NBP1-43458] - Staining of rat splenocytes with 0.25 ug of Mouse IgG3 Isotype control (open histogram) or 0.25 ug of Anti-Rat CD3 (filled histogram) followed by anti-Mouse IgG Biotin and Streptavidin PE.Applications for CD3 Antibody (G4.18) - BSA Free
Application
Recommended Usage
Flow Cytometry
1:10 - 1:1000
Immunohistochemistry
1:10 - 1:500
Immunohistochemistry-Paraffin
1:10 - 1:500
Immunoprecipitation
1:10 - 1:500
Western Blot
1:100 - 1:2000
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Formulation
PBS (pH 7.2)
Format
BSA Free
Preservative
0.09% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C. Do not freeze.
Background: CD3
CD3 proteins are expressed on the surface of thymocytes during thymocyte development, proliferation, and maturation to T-cells (4, 6, 7). During T-cell development CD4-CD8- double negative (DN) cells differentiate to CD4+CD8+ double positive (DP) cells before progressing to single positive (SP) CD4+ helper T-cells or CD8+ cytotoxic T-cells (4, 6, 7). As CD3 plays an important role in thymocyte development, it is understandable that CD3 defects and mutations in CD3 protein chains cause severe combined immunodeficiencies (SCIDs) (8). Additionally, a subset of CD3+ T-cells that co-express CD20 are described in a variety of diseases including rheumatoid arthritis, multiple sclerosis, CD20+ T-cell leukemia/lymphoma, and HIV (9). Clinical trials and animal models have shown that anti-CD3 monoclonal antibodies are a promising treatment modality for inflammatory disorders and autoimmune diseases, such as type I diabetes (10).
References
1. Chetty, R., & Gatter, K. (1994). CD3: structure, function, and role of immunostaining in clinical practice. The Journal of pathology. https://doi.org/10.1002/path.1711730404
2. Mariuzza, R. A., Agnihotri, P., & Orban, J. (2020). The structural basis of T-cell receptor (TCR) activation: An enduring enigma. The Journal of biological chemistry. https://doi.org/10.1074/jbc.REV119.009411
3. Kuhns, M. S., Davis, M. M., & Garcia, K. C. (2006). Deconstructing the form and function of the TCR/CD3 complex. Immunity. https://doi.org/10.1016/j.immuni.2006.01.006
4. Clevers, H., Alarcon, B., Wileman, T., & Terhorst, C. (1988). The T cell receptor/CD3 complex: a dynamic protein ensemble. Annual review of immunology. https://doi.org/10.1146/annurev.iy.06.040188.003213
5. Uniprot: CD3-delta (P04234), CD3-epsilon (P07766), CD3-gamma (P09693), CD3-zeta (P20963)
6. D'Acquisto, F., & Crompton, T. (2011). CD3+CD4-CD8- (double negative) T cells: saviours or villains of the immune response?. Biochemical pharmacology. https://doi.org/10.1016/j.bcp.2011.05.019
7. Dave V. P. (2009). Hierarchical role of CD3 chains in thymocyte development. Immunological reviews. https://doi.org/10.1111/j.1600-065X.2009.00835.x
8. Fischer, A., de Saint Basile, G., & Le Deist, F. (2005). CD3 deficiencies. Current opinion in allergy and clinical immunology. https://doi.org/10.1097/01.all.0000191886.12645.79
9. Chen, Q., Yuan, S., Sun, H., & Peng, L. (2019). CD3+CD20+ T cells and their roles in human diseases. Human immunology. https://doi.org/10.1016/j.humimm.2019.01.001
10. Kuhn, C., & Weiner, H. L. (2016). Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. Immunotherapy. https://doi.org/10.2217/imt-2016-0049
Alternate Names
CD_antigen: CD3e, CD3 antigen, delta subunit, CD3d antigen, CD3d antigen, delta polypeptide (TiT3 complex), CD3d molecule, delta (CD3-TCR complex), CD3-DELTA, CD3e, CD3e antigen, CD3e antigen, epsilon polypeptide (TiT3 complex), CD3e molecule, epsilon (CD3-TCR complex), CD3-epsilon, CD3G, CD3g antigen, CD3g antigen, gamma polypeptide (TiT3 complex), CD3g molecule, epsilon (CD3-TCR complex), CD3g molecule, gamma (CD3-TCR complex), CD3-GAMMA, FLJ17620, FLJ17664, FLJ18683, FLJ79544, FLJ94613, IMD18, MGC138597, T3DOKT3, delta chain, T3E, T-cell antigen receptor complex, epsilon subunit of T3, T-cell receptor T3 delta chain, T-cell surface antigen T3/Leu-4 epsilon chain, T-cell surface glycoprotein CD3 delta chain, T-cell surface glycoprotein CD3 epsilon chain, TCRE
Gene Symbol
CD3E
Additional CD3 Products
Product Documents for CD3 Antibody (G4.18) - BSA Free
Product Specific Notices for CD3 Antibody (G4.18) - BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...